Best of ASCO - 2014 Annual Meeting

 

Welcome

Cellular Immunotherapy

Developmental Therapeutics—Immunotherapy

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Robert F. Cornell

TPS3103

A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers.

Partow Kebriaei

TPS3104

A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).

J. Randolph Hecht

TPS3105

A phase 2 study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (TIL, LN-145) alone and in combination with anti-PD-L1 inhibitor durvalumab in patients with locally advanced or metastatic NSCLC.

Sylvia Mina Lee

TPS3107

A phase I trial of PD-1 deficient engineered T cells with CRISPR/Cas9 in patients with advanced non-small cell lung cancer.

You Lu

3050

A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).

Sophie Papa

3046

A retrospective study of 83 pancreatic cancer patients treated by combining chemotherapy with NK cell-enriched immunotherapy.

Kenta Narumi

e15063

Acquired resistance to T cell adoptive transfer by inflammation-induced melanoma dedifferentiation.

Arnav Mehta

3047

Activity of CAR19 T cells secreting ​impact fusion proteins against hematopoietic and solid tumors.

Fay Dufort

e15046

Adoptive cellular immunotherapy with APN401, autologous cbl-b silenced peripheral blood mononuclear cells: Data from a phase I study in patients with solid tumors.

Hans Loibner

3055

An examination of the use of CD19 CAR NK-92 cells to induce complete remission and vaccine effect against rechallenge in a highly aggressive murine leukemia.

Nathan Thomas Schomer

e15034

Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.

Jesus G. Berdeja

e15062

Characterization of two potential immunotherapeutics in tumor infiltrating lymphocytes (TILs) using flow cytometry and Meso Scale Discovery.

Karen K Yam

e15052

Chimeric antigen receptor-t cells (CAR-T) horizon scanning: Emerging targets in oncology and hematology.

Quentin Dardonville

e15031

Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.

Jennifer N. Brudno

3052

Combination immunotherapy selection for non-PD-1 axis driven tumors.

Carl Morrison

e15058

Combination of cellular immunotherapy and rituximab-based regimens in patients with diffuse large B cell lymphoma: A pilot cohort study.

Jiu Wei Cui

e15044

Considerations for tisagenlecleucel dosing rationale.

Rakesh Awasthi

e15056

Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy.

Vinodh Pillai

3051

Development of an allogeneic product by CAR-T cells TCR knock-down.

Susanna Raitano

e15040

Development of NKG2D chimeric antigen receptor-T cells as targeted therapy of liver cancer.

Hong-jiu Dai

e15057

Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.

Frederick Lundry Locke

3003

Durable clinical responses observed from non-Hodgkin lymphoma patients treated with autologous CAR-T cells targeting CD19.

Yarong Liu

3045

Effect of immunotherapy of triple negative breast cancer with ROR1 CAR T cells in combination with the TGF-ß receptor I kinase inhibitor SD-208.

Tanja Stüber

e15050

Effect of RNAi-based β-catenin inhibition on immunosuppressive Wnt-activated tumors in combination with IDOi/PD-1 immunotherapy.

Shanthi Ganesh

e15038

Effective screening of neoantigen-specific cytotoxic t cells.

Tatsuo Matsuda

e15061

Engineered t cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Benjamin Y Jin

e15048

ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study.

Zhi Tao Ying

3049

Ex vivo expanded multi-antigen specific lymphocytes for the treatment of solid tumors.

Amy Houghtelin

3042

First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors.

Timothy Anthony Yap

3040

Genetically engineered T-cell therapy for HPV-associated epithelial cancers: A first in human, phase I/II clinical trial.

Stacey L. Doran

3019

Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.

Karen Thudium Mueller

3044

Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).

Ragisha Gopalakrishnan

3053

Individualized cancer vaccine to elicit tumor debulking immunity in advanced HCC.

Michael Har-Noy

e15054

Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

Vincent K. Lam

3056

Neoantigen-based personalized, immune cell therapy for patients with advanced NSCLC: A pilot study.

Zhenyu Ding

e15043

Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.

Frederick Lundry Locke

3039

Patient specific characteristics associated with T-cell expansion for HER2/neu vaccine-primed autologous adoptive T-cell therapy.

Lisa May Ling Tachiki

e15041

Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.

Apostolia Maria Tsimberidou

TPS3106

Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.

Sandra P. D'Angelo

3005

Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.

Nisha Nagarsheth

3043

Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease.

Joshua Kellner

e15047

Retronectin and anti-CD3 monoclonal antibody actived T cell combined anti-PD-1 therapy in heavy-treated renal cell cancer.

Ling-Di Zhao

e15053

Safety and activity of programmed cell death-1 gene knockout engineered t cells in patients with previously treated advanced esophageal squamous cell carcinoma: An open-label, single-arm phase I study.

Zhao Jing

3054

Screening of neoantigen-specific T cells and establishment of T-cell receptor-engineered T cells: Implications for head and neck squamous carcinoma.

Lili Ren

3048

TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach.

David Edward Gilham

e15042

Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells.

Sanja Stevanovic

3004

Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.

Peihua Lu

3041

ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.

Michael Wang

TPS3102